CA2649194C - Pharmaceutical composition that comprises an analgesic and vitamins - Google Patents

Pharmaceutical composition that comprises an analgesic and vitamins Download PDF

Info

Publication number: CA2649194C
Authority: CA; Canada
Prior art keywords: ketorolac; pharmaceutical composition; composition according; complex; solution
Prior art date: 2006-04-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA2649194A

Other languages

English (en)

French (fr)

Other versions

CA2649194A1 (en

Inventor

Enrique Raul Garcia-Salgado Lopez

Gustavo Barranco Hernandez

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Laboratorios Senosiain SA de CV

Original Assignee

Laboratorios Senosiain SA de CV

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-04-10

Filing date

2007-04-10

Publication date

2014-12-30

2006-04-10 Priority claimed from MXPA/A/2006/004020A external-priority patent/MXPA06004020A/es

2007-04-10 Application filed by Laboratorios Senosiain SA de CV filed Critical Laboratorios Senosiain SA de CV

2007-10-18 Publication of CA2649194A1 publication Critical patent/CA2649194A1/en

2014-12-30 Application granted granted Critical

2014-12-30 Publication of CA2649194C publication Critical patent/CA2649194C/en

Status Expired - Fee Related legal-status Critical Current

2027-04-10 Anticipated expiration legal-status Critical

Links

239000008194 pharmaceutical composition Substances 0.000 title claims description 31
229940088594 vitamin Drugs 0.000 title claims description 13
229930003231 vitamin Natural products 0.000 title claims description 13
235000013343 vitamin Nutrition 0.000 title claims description 13
239000011782 vitamin Substances 0.000 title claims description 13
230000000202 analgesic effect Effects 0.000 title description 10
OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical class OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims abstract description 102
208000002193 Pain Diseases 0.000 claims abstract description 16
230000036407 pain Effects 0.000 claims abstract description 16
208000004296 neuralgia Diseases 0.000 claims abstract description 5
239000000203 mixture Substances 0.000 claims description 53
239000000243 solution Substances 0.000 claims description 48
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
238000009472 formulation Methods 0.000 claims description 17
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
239000003814 drug Substances 0.000 claims description 9
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 8
DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 8
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
229960004384 ketorolac tromethamine Drugs 0.000 claims description 7
BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 claims description 7
238000007911 parenteral administration Methods 0.000 claims description 7
239000000872 buffer Substances 0.000 claims description 6
239000003755 preservative agent Substances 0.000 claims description 6
239000006184 cosolvent Substances 0.000 claims description 5
239000003795 chemical substances by application Substances 0.000 claims description 4
235000019441 ethanol Nutrition 0.000 claims description 4
238000007918 intramuscular administration Methods 0.000 claims description 4
150000003722 vitamin derivatives Chemical class 0.000 claims description 3
238000001990 intravenous administration Methods 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
238000002156 mixing Methods 0.000 claims description 2
239000003182 parenteral nutrition solution Substances 0.000 claims description 2
RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 claims 8
229960002104 cyanocobalamin Drugs 0.000 claims 4
235000000639 cyanocobalamin Nutrition 0.000 claims 4
239000011666 cyanocobalamin Substances 0.000 claims 4
ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims 4
229960004172 pyridoxine hydrochloride Drugs 0.000 claims 4
235000019171 pyridoxine hydrochloride Nutrition 0.000 claims 4
239000011764 pyridoxine hydrochloride Substances 0.000 claims 4
235000019190 thiamine hydrochloride Nutrition 0.000 claims 4
239000011747 thiamine hydrochloride Substances 0.000 claims 4
229960000344 thiamine hydrochloride Drugs 0.000 claims 4
235000019191 thiamine mononitrate Nutrition 0.000 claims 2
239000011748 thiamine mononitrate Substances 0.000 claims 2
229960004860 thiamine mononitrate Drugs 0.000 claims 2
UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 claims 2
239000006174 pH buffer Substances 0.000 claims 1
229940097022 thiamine 100 mg Drugs 0.000 claims 1
229960004752 ketorolac Drugs 0.000 abstract description 95
230000002195 synergetic effect Effects 0.000 abstract description 11
238000000034 method Methods 0.000 abstract description 6
AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 63
230000000694 effects Effects 0.000 description 43
229960002477 riboflavin Drugs 0.000 description 38
239000002151 riboflavin Substances 0.000 description 37
AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 32
235000019192 riboflavin Nutrition 0.000 description 31
230000003502 anti-nociceptive effect Effects 0.000 description 23
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 17
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 17
LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 14
229960003495 thiamine Drugs 0.000 description 13
241000700159 Rattus Species 0.000 description 12
AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 12
230000007423 decrease Effects 0.000 description 12
239000000546 pharmaceutical excipient Substances 0.000 description 12
239000008215 water for injection Substances 0.000 description 12
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
231100000673 dose–response relationship Toxicity 0.000 description 11
238000003756 stirring Methods 0.000 description 11
KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 11
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 10
230000000996 additive effect Effects 0.000 description 10
238000012360 testing method Methods 0.000 description 10
230000001225 therapeutic effect Effects 0.000 description 10
JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 9
230000002411 adverse Effects 0.000 description 9
235000019157 thiamine Nutrition 0.000 description 9
239000011721 thiamine Substances 0.000 description 9
230000006870 function Effects 0.000 description 8
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 8
230000003040 nociceptive effect Effects 0.000 description 8
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 8
235000010374 vitamin B1 Nutrition 0.000 description 8
239000011691 vitamin B1 Substances 0.000 description 8
239000002253 acid Substances 0.000 description 7
230000003110 anti-inflammatory effect Effects 0.000 description 7
230000003993 interaction Effects 0.000 description 7
239000000047 product Substances 0.000 description 7
235000019158 vitamin B6 Nutrition 0.000 description 7
239000011726 vitamin B6 Substances 0.000 description 7
229940011671 vitamin b6 Drugs 0.000 description 7
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 6
229940005483 opioid analgesics Drugs 0.000 description 6
239000000843 powder Substances 0.000 description 6
239000000126 substance Substances 0.000 description 6
235000019163 vitamin B12 Nutrition 0.000 description 6
239000011715 vitamin B12 Substances 0.000 description 6
241000206575 Chondrus crispus Species 0.000 description 5
239000004480 active ingredient Substances 0.000 description 5
230000008901 benefit Effects 0.000 description 5
229960004106 citric acid Drugs 0.000 description 5
229940079593 drug Drugs 0.000 description 5
229930003451 Vitamin B1 Natural products 0.000 description 4
230000006399 behavior Effects 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 4
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 4
229960002216 methylparaben Drugs 0.000 description 4
229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 4
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 4
229960003415 propylparaben Drugs 0.000 description 4
RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 4
230000004044 response Effects 0.000 description 4
AEDORKVKMIVLBW-BLDDREHASA-N 3-oxo-3-[[(2r,3s,4s,5r,6r)-3,4,5-trihydroxy-6-[[5-hydroxy-4-(hydroxymethyl)-6-methylpyridin-3-yl]methoxy]oxan-2-yl]methoxy]propanoic acid Chemical compound OCC1=C(O)C(C)=NC=C1CO[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)CC(O)=O)O1 AEDORKVKMIVLBW-BLDDREHASA-N 0.000 description 3
208000019901 Anxiety disease Diseases 0.000 description 3
229920002261 Corn starch Polymers 0.000 description 3
108010037464 Cyclooxygenase 1 Proteins 0.000 description 3
108010037462 Cyclooxygenase 2 Proteins 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
229920000168 Microcrystalline cellulose Polymers 0.000 description 3
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
229910019142 PO4 Inorganic materials 0.000 description 3
102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 3
102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 3
102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 3
108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 3
229930003779 Vitamin B12 Natural products 0.000 description 3
239000000654 additive Substances 0.000 description 3
230000036506 anxiety Effects 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
239000008120 corn starch Substances 0.000 description 3
229960001259 diclofenac Drugs 0.000 description 3
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 3
230000001079 digestive effect Effects 0.000 description 3
238000004090 dissolution Methods 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
238000007726 management method Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
235000019813 microcrystalline cellulose Nutrition 0.000 description 3
239000008108 microcrystalline cellulose Substances 0.000 description 3
229940016286 microcrystalline cellulose Drugs 0.000 description 3
229960003512 nicotinic acid Drugs 0.000 description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
239000010452 phosphate Substances 0.000 description 3
239000001267 polyvinylpyrrolidone Substances 0.000 description 3
235000008160 pyridoxine Nutrition 0.000 description 3
239000011677 pyridoxine Substances 0.000 description 3
239000011734 sodium Substances 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
235000019156 vitamin B Nutrition 0.000 description 3
239000011720 vitamin B Substances 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
PYASDJRYVQOSJZ-UHFFFAOYSA-N 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol hypochlorous acid Chemical compound ClO.CC1=NC=C(CO)C(CO)=C1O PYASDJRYVQOSJZ-UHFFFAOYSA-N 0.000 description 2
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
229910002012 Aerosil® Inorganic materials 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
208000032843 Hemorrhage Diseases 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
206010028851 Necrosis Diseases 0.000 description 2
206010029240 Neuritis Diseases 0.000 description 2
RVSTWRHIGKXTLG-UHFFFAOYSA-N Pangamic acid Natural products CC(C)N(C(C)C)C(N(C(C)C)C(C)C)C(=O)OCC(O)C(O)C(O)C(O)C(O)=O RVSTWRHIGKXTLG-UHFFFAOYSA-N 0.000 description 2
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
208000004756 Respiratory Insufficiency Diseases 0.000 description 2
206010038678 Respiratory depression Diseases 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
208000034158 bleeding Diseases 0.000 description 2
231100000319 bleeding Toxicity 0.000 description 2
230000000740 bleeding effect Effects 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
235000021552 granulated sugar Nutrition 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000012528 membrane Substances 0.000 description 2
230000017074 necrotic cell death Effects 0.000 description 2
239000013642 negative control Substances 0.000 description 2
210000000653 nervous system Anatomy 0.000 description 2
235000001968 nicotinic acid Nutrition 0.000 description 2
239000011664 nicotinic acid Substances 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
239000000014 opioid analgesic Substances 0.000 description 2
-1 other NSAIDs Chemical compound 0.000 description 2
ZQTHOIGMSJMBLM-BUJSFMDZSA-N pangamic acid Chemical compound CN(C)CC(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O ZQTHOIGMSJMBLM-BUJSFMDZSA-N 0.000 description 2
108700024047 pangamic acid Proteins 0.000 description 2
230000008569 process Effects 0.000 description 2
150000003180 prostaglandins Chemical class 0.000 description 2
239000008213 purified water Substances 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
230000001235 sensitizing effect Effects 0.000 description 2
238000009987 spinning Methods 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000008107 starch Substances 0.000 description 2
230000003637 steroidlike Effects 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
206010010774 Constipation Diseases 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
241000282414 Homo sapiens Species 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
206010065390 Inflammatory pain Diseases 0.000 description 1
206010022653 Intestinal haemorrhages Diseases 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
206010036105 Polyneuropathy Diseases 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
239000008156 Ringer's lactate solution Substances 0.000 description 1
206010039897 Sedation Diseases 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
229930003270 Vitamin B Natural products 0.000 description 1
229930003471 Vitamin B2 Natural products 0.000 description 1
229930003537 Vitamin B3 Natural products 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
208000010045 Wernicke encephalopathy Diseases 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
230000016571 aggressive behavior Effects 0.000 description 1
230000001618 algogenic effect Effects 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
230000036592 analgesia Effects 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
229960004543 anhydrous citric acid Drugs 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000001754 anti-pyretic effect Effects 0.000 description 1
230000003356 anti-rheumatic effect Effects 0.000 description 1
239000002221 antipyretic Substances 0.000 description 1
239000003435 antirheumatic agent Substances 0.000 description 1
230000036528 appetite Effects 0.000 description 1
235000019789 appetite Nutrition 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
230000002051 biphasic effect Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
150000001642 boronic acid derivatives Chemical class 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
230000002425 cardiocirculatory effect Effects 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
238000010523 cascade reaction Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
208000019902 chronic diarrheal disease Diseases 0.000 description 1
208000033630 chronic polyneuropathy Diseases 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
210000002249 digestive system Anatomy 0.000 description 1
239000000428 dust Substances 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical group CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
125000005909 ethyl alcohol group Chemical group 0.000 description 1
239000003925 fat Substances 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
238000005243 fluidization Methods 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
230000000642 iatrogenic effect Effects 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
230000006872 improvement Effects 0.000 description 1
229960000905 indomethacin Drugs 0.000 description 1
239000005550 inflammation mediator Substances 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000000622 irritating effect Effects 0.000 description 1
230000007803 itching Effects 0.000 description 1
238000009533 lab test Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
229960001929 meloxicam Drugs 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
230000008693 nausea Effects 0.000 description 1
230000000626 neurodegenerative effect Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
210000000929 nociceptor Anatomy 0.000 description 1
108091008700 nociceptors Proteins 0.000 description 1
238000010979 pH adjustment Methods 0.000 description 1
229940055705 pangamic acid Drugs 0.000 description 1
229960005489 paracetamol Drugs 0.000 description 1
230000001769 paralizing effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
208000019629 polyneuritis Diseases 0.000 description 1
230000007824 polyneuropathy Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000011514 reflex Effects 0.000 description 1
210000005084 renal tissue Anatomy 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
230000036280 sedation Effects 0.000 description 1
230000035807 sensation Effects 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
229940045902 sodium stearyl fumarate Drugs 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
239000011493 spray foam Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
230000008961 swelling Effects 0.000 description 1
239000000454 talc Chemical group 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
150000003595 thromboxanes Chemical class 0.000 description 1
230000001256 tonic effect Effects 0.000 description 1
229960004380 tramadol Drugs 0.000 description 1
TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
230000009466 transformation Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
235000019164 vitamin B2 Nutrition 0.000 description 1
239000011716 vitamin B2 Substances 0.000 description 1
235000019160 vitamin B3 Nutrition 0.000 description 1
239000011708 vitamin B3 Substances 0.000 description 1
235000021468 vitamin B8 Nutrition 0.000 description 1
229940047044 vitamin b 12 5 mg Drugs 0.000 description 1
229940046001 vitamin b complex Drugs 0.000 description 1
230000008673 vomiting Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Molecular Biology (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

CA2649194A 2006-04-10 2007-04-10 Pharmaceutical composition that comprises an analgesic and vitamins Expired - Fee Related CA2649194C (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
MXPA/A/2006/004020		2006-04-10
MXPA/A/2006/004020A MXPA06004020A (es)		2006-04-10	Composicion farmaceutica que comprende un analgesico y vitaminas
PCT/IB2007/000907 WO2007116287A1 (es)	2006-04-10	2007-04-10	Composición farmacéutica que comprende la combinación de una sal de ketorolaco y vitaminas del complejo b para el tratamiento de la neuralgia.

Publications (2)

Publication Number	Publication Date
CA2649194A1 CA2649194A1 (en)	2007-10-18
CA2649194C true CA2649194C (en)	2014-12-30

Family

ID=38580737

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2649194A Expired - Fee Related CA2649194C (en)	2006-04-10	2007-04-10	Pharmaceutical composition that comprises an analgesic and vitamins

Country Status (16)

Country	Link
US (1)	US20090227534A1 (es)
EP (1)	EP2008655B1 (es)
JP (1)	JP5244089B2 (es)
AR (1)	AR060394A1 (es)
BR (1)	BRPI0709967A2 (es)
CA (1)	CA2649194C (es)
CO (1)	CO6331430A2 (es)
CR (1)	CR10360A (es)
DO (1)	DOP2007000055A (es)
EC (1)	ECSP088801A (es)
ES (1)	ES2428342T3 (es)
GT (1)	GT200800208A (es)
HN (1)	HN2008001531A (es)
PE (2)	PE20080363A1 (es)
PL (1)	PL2008655T3 (es)
WO (1)	WO2007116287A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX2008003230A (es) *	2008-03-07	2009-09-07	Senosiain S A De C V Lab	Composicion famaceutica oral que comprende la combinacion de una sal de ketorolaco y vitaminas del complejo b.
KR20190085561A (ko)	2010-10-21	2019-07-18	알티유 파머수티컬즈, 엘엘시	즉시 사용가능한 케토로락 제제
AU2013201465B2 (en) *	2012-10-24	2016-03-03	Rayner Intraocular Lenses Limited	Stable preservative-free mydriatic and anti-inflammatory solutions for injection
TWI809304B (zh)	2014-12-01	2023-07-21	奥默羅斯公司	用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2823167A (en) *	1955-03-29	1958-02-11	Vitarine Co Inc	Stable vitamin b12-containing solution
FR4492M (es) *	1965-07-07	1966-10-10
US4579846A (en) *	1984-10-11	1986-04-01	Pfizer Inc.	Antiinflammatory compositions and methods
US6051587A (en)	1998-04-16	2000-04-18	Medicure, Inc.	Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein
US20030191187A1 (en) *	2002-04-01	2003-10-09	Lee Fang Yu	Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
US9668972B2 (en) *	2002-10-25	2017-06-06	Foamix Pharmaceuticals Ltd.	Nonsteroidal immunomodulating kit and composition and uses thereof
MXPA02010828A (es)	2002-11-04	2004-07-16	Leopoldo Espinosa Abdala	Composicion farmaceutica en capsulas que comprende un antiinflamatorio no esteroideo y un analgesico opiaceo para el manejo del dolor.

2007
- 2007-03-22 DO DO2007000055A patent/DOP2007000055A/es unknown
- 2007-04-09 PE PE2007000424A patent/PE20080363A1/es not_active Application Discontinuation
- 2007-04-09 PE PE2011001166A patent/PE20120122A1/es active IP Right Grant
- 2007-04-10 CA CA2649194A patent/CA2649194C/en not_active Expired - Fee Related
- 2007-04-10 WO PCT/IB2007/000907 patent/WO2007116287A1/es not_active Ceased
- 2007-04-10 PL PL07734226T patent/PL2008655T3/pl unknown
- 2007-04-10 AR ARP070101491A patent/AR060394A1/es not_active Application Discontinuation
- 2007-04-10 ES ES07734226T patent/ES2428342T3/es active Active
- 2007-04-10 EP EP07734226.9A patent/EP2008655B1/en not_active Not-in-force
- 2007-04-10 JP JP2009504843A patent/JP5244089B2/ja not_active Expired - Fee Related
- 2007-04-10 BR BRPI0709967-3A patent/BRPI0709967A2/pt not_active IP Right Cessation
- 2007-04-10 US US12/226,219 patent/US20090227534A1/en not_active Abandoned
2008
- 2008-10-08 EC EC2008008801A patent/ECSP088801A/es unknown
- 2008-10-09 GT GT200800208A patent/GT200800208A/es unknown
- 2008-10-10 HN HN2008001531A patent/HN2008001531A/es unknown
- 2008-10-10 CO CO08108827A patent/CO6331430A2/es not_active Application Discontinuation
- 2008-10-10 CR CR10360A patent/CR10360A/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
PL2008655T3 (pl)	2013-11-29
JP5244089B2 (ja)	2013-07-24
BRPI0709967A2 (pt)	2011-08-02
CA2649194A1 (en)	2007-10-18
CO6331430A2 (es)	2011-10-20
US20090227534A1 (en)	2009-09-10
CR10360A (es)	2009-02-20
PE20080363A1 (es)	2008-05-25
WO2007116287A1 (es)	2007-10-18
ES2428342T3 (es)	2013-11-07
HN2008001531A (es)	2011-07-12
EP2008655B1 (en)	2013-06-26
PE20120122A1 (es)	2012-03-09
DOP2007000055A (es)	2007-10-31
JP2009533413A (ja)	2009-09-17
ECSP088801A (es)	2009-01-30
GT200800208A (es)	2010-03-18
EP2008655A1 (en)	2008-12-31
AR060394A1 (es)	2008-06-11

Publication	Publication Date	Title
Chermy et al.	1993	Cancer pain management current strategy
ES2435240T3 (es)	2013-12-17	Composiciones de dosis fija farmacéuticas sólidas que comprenden irbesartán y amlodipina, su preparación y su aplicación terapéutica
BRPI0613499A2 (pt)	2011-01-11	formulação de comprimido farmacêutico de 1[(3-hidróxi-adamant -1-ilamino)- acetil]- pirrolidino-2 (s)-carbonitrila de liberação modificada, comprimido em multicamada, comprimido farmacêutico e cápsula contendo a mesma, processo de produção da mesma, seu uso, processo de preparação de comprimido bem como forma de dosagem farmacêutica
BG65502B1 (bg)	2008-10-31	Фармацевтичен състав за лечение на остри неразположения и неговото използване
TW200418474A (en)	2004-10-01	Method of treating post-operative nausea and vomiting
US20060211686A1 (en)	2006-09-21	Alpha7 Neuronal nicotinic receptor ligand and antipsychotic compositions
CA2649194C (en)	2014-12-30	Pharmaceutical composition that comprises an analgesic and vitamins
CA2490147C (en)	2014-01-14	Liquid dosage forms of non-enterically coated proton pump inhibitors
JPH0157093B2 (es)	1989-12-04
CN118401241A (zh)	2024-07-26	用于治疗慢性肾脏病的醛固酮合成酶抑制剂
CN109865139B (zh)	2021-07-20	一种阿利沙坦酯或其盐与钙离子通道拮抗剂的复方药物组合物
RU2261098C2 (ru)	2005-09-27	Перорально распадающаяся композиция, содержащая миртазапин
JP7745086B2 (ja)	2025-09-26	ＡＲＮｉとカルシウムイオンアンタゴニストとの医薬組成物および応用
BRPI0908988A2 (pt)	2020-08-04	formulação galênica oral incluindo cetorolaco e vitaminas do complexo b, em que a vitamina b6 está em uma camada externa separada do resto dos princípios ativos
US9186342B2 (en)	2015-11-17	Combination of an NSAID and an amino acid
KR20120104574A (ko)	2012-09-21	티보자닙과 템시롤리무스의 조합물
MXPA06004020A (es)	2006-10-17	Composicion farmaceutica que comprende un analgesico y vitaminas
EP1553934A1 (en)	2005-07-20	Pharmaceutical composition for treating pain comprising oxicarbazepine, or derivatives thereof, and cox2 inhibitors
US10154963B2 (en)	2018-12-18	Controlled-release formulations comprising Torsemide
CN102335177B (zh)	2013-05-01	一种口服固体药用组合物及其制备方法
MX2011013989A (es)	2013-06-17	Combinacion farmaceutica.
US20250345324A1 (en)	2025-11-13	Combination formulations of naloxone and atipamezole
JP4344532B2 (ja)	2009-10-14	鼻炎用組成物
US20060063813A1 (en)	2006-03-23	Organic compounds
TW200838534A (en)	2008-10-01	Treatment for irritable bowel syndrome

Legal Events

Date	Code	Title	Description
2012-04-10	EEER	Examination request
2020-10-13	MKLA	Lapsed	Effective date: 20200831